Universal regimens or universal access to drug susceptibility testing for tuberculosis?

Lancet Infect Dis. 2019 Mar;19(3):224-225. doi: 10.1016/S1473-3099(18)30742-4. Epub 2019 Feb 8.

Authors

Rebecca Acquah¹, Jennifer Furin²

Affiliations

¹ Médecins Sans Frontières, Eshowe, South Africa.
² Harvard Medical School, Department of Global Health and Social Medicine, Boston, MA 02115, USA. Electronic address: jenniferfurin@gmail.com.

PMID: 30744961
DOI: 10.1016/S1473-3099(18)30742-4

No abstract available

Publication types

Comment

MeSH terms

Humans
Microbial Sensitivity Tests
Mycobacterium tuberculosis*
Tuberculosis*
Tuberculosis, Multidrug-Resistant*